FDA grants AstraZeneca saracatinib an orphan drug for myocotic pulmonary fibrosis

IPF is a rare lung disease that causes fatal, irreversible, progressive lung scars (fibrosis), which can cause breathing difficulties and prevent the heart, muscles and critical organs from getting enough oxygen to function properlyIPF progresses quickly and slowly, but ultimately leads to a repeal hardening and stopworking, AstraZeneca, thehttp:// pharmaceuticalgiant, announced that theAuthority for food anddrugs (http:// had granted saracatinib an orphan drug for the treatment of iacotic pulmonary fibrosis (IPF) by theAuthority of theFDA (http://)about saracatinibSaracatinib was discovered by AstraZeneca as an SCR kinase inhibitor that regulates a wide range of cellular functions, including cell growth and cell differentiationPreviously, AstraZeneca has been evaluating saracatinib for use in oncology, a drug that has not yet been initiated in phase II clinical treatment of IPFOrphan medicine refers to themedicine(http://used to prevent, treat and diagnose rare diseases, which are a category of very low incidence of diseases, also known as "orphan diseases" in the United States, a rare disease is a type of disease that affects fewer than 200,000 people Pharmaceutical companies that develop rare disease drugs (http:// will receive incentives, including a variety of clinical development incentives, such as tax credits related to clinical trial (http:// fees, FDA user fee waivers, FDA assistance in clinical trial designs, and a seven-year market-exclusive period after the drug is approved for market release